Abstract:OBJECTIVE:To observe the effects of gene therapy and epigenetic therapy on the tumor growth of laryngeal carcinoma and the underlying mechanisms.METHODS:The animal model of human laryngeal carcinoma was established by the subcutaneous inoculation of Hep-2 cells at the right armpit of BALB/c nu/nu mice. The tumor-bearing mice were randomized into 4 groups, p53 therapy group(rAd-p53), epigenetic therapy group(5-aza-dC), combination therapy group (rAd-p53+5-aza-dC) and control group. The gene and protein expressions of molecular markers p53 and E-cadherin were detected by FQ-PCR and immunohistochemistry.RESULTS:By the day 20 of the treatments, the mean tumor volumes were(106.09 ± 24.40)mm(3) in p53 therapy group, (166.55 ± 40.11) mm(3) in epigenetic therapy group, (126.11 ± 22.49) mm(3) in combination therapy group,and (252.83 ± 54.09) mm(3) in control group. Both gene therapy (F = 37.30, P < 0.05) and epigenetic therapy (F = 4.79, P < 0.05) inhibited the growth of xenografted tumors, with an interaction effect (F = 22.01, P < 0.05) between the two groups. The integral optical density value of p53 protein expression of p53 therapy group (628.07 ± 95.16) was significantly higher than that of combination therapy group (494.76 ± 100.22), (t = 8.72, P < 0.05). The integral optical density values of E-cadherin protein expression were 558.89 ± 97.58 in p53 therapy group, 380.41 ± 90.60 in epigenetic therapy group, 494.76 ± 102.88 in combination therapy group,and 162.60 ± 40.38 in control group respectively, indicating the enhancements of E-cadherin protein expression by gene therapy (F = 45.24, P < 0.05) or epigenetic therapy(F = 5.73, P < 0.05)and the existence of interaction effect (F = 21.82, P < 0.05) between gene therapy and epigenetic therapy. The expression levels of p53 gene were 4.43 ± 0.12 in p53 therapy group, 1.06 ± 0.11 in epigenetic therapy group, 3.51 ± 0.10 in combination therapy group,and 1.09 ± 0.11 in control group, respectively, showing an interaction effect between gene therapy and epigenetic therapy (F = 298.11, P < 0.05). The expression levels of E-cadherin gene were 4.50 ± 0.34 in p53 therapy group, 2.02 ± 0.16 in epigenetic therapy group, 2.99 ± 0.12 in combination therapy group, and 1.00 ± 0.11 in control group, respectively. The expression of E-cadherin gene was enhanced by gene therapy (F = 329.12, P < 0.05)or epigenetic therapy(F = 88.57, P < 0.05), with an interaction effect between the two therapies (F = 122.17, P < 0.05).CONCLUSIONS:Xenografted tumors of human laryngeal carcinoma cells are inhibited by gene therapy, the epigenetic therapy and the combination therapy. The gene therapy was significantly better than the epigenetic therapy or the combination therapy. There might be antagonistic effect between p53 and 5-aza-dC.

Signal Transduction-Related Gene Transfer Leads to Inhibition of Proliferation and Induction of Differentiation in Laryngeal Squamous Cell Carcinoma in Vitro.

Combined P14(Arf) And Antisense Egfr Potentiate The Efficacy Of Adenovirus-Mediated Gene Therapy In Laryngeal Squamous Cell Carcinoma (Lscc)

Interference Therapy of Laryngeal Squamous Cell Carcinoma by p16β and EGFR-Antisense cDNA in Signal Transduction

[Study on Interference Therapy Induced by Epidermal Growth Factor Receptor-Antisense Cdna in Signal Transduction of Laryngeal Squamous Cell Carcinoma].

Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line

Expression and Purification of FGFR1-Fc Fusion Protein and Its Effects on Human Lung Squamous Carcinoma

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

The Construction and Characterization of a Novel Adenovirus Vector of Artificial Microrna Targeting EGFR.

[Adenovirus P16(ink4a) Gene Therapy for Laryngeal Squamous Cell Carcinoma].

Inhibitory Effects of 5-Aza-2′-deoxycytidine and Trichostatin A in Combination with P53-Expressing Adenovirus on Human Laryngocarcinoma Cells

Inhibition of Human Laryngeal Carcinoma Growth by Gene Therapy and Epigenetic Therapy

The In Vitro And In Vivo Antitumor Activity Of Adenovirus-Mediated Interleukin-24 Expression For Laryngocarcinoma

[Study in Vitro on P16beta Interfering the Cell Cycle Signal Conduction of Laryngeal Squamous Cell Carcinoma].

Antitumor Potential of SLPI Promoter Controlled Recombinant Caspase-3 Expression in Laryngeal Carcinoma

Cell-Specific Expression of Artificial Micrornas Targeting Essential Genes Exhibit Potent Antitumor Effect on Hepatocellular Carcinoma Cells

[Construction of Recombinant Adenovirus Vector Carrying Cell Cycle Controlling Gene-P14arf].

Adenovirus-mediated Tissue-Specific Cytosine Deaminase Gene Therapy for Human Hepatocellular Carcinoma with Different AFP Expression Levels.

Application of combination of short hairpin RNA segments for silencing VEGF, TERT and Bcl-xl expression in laryngeal squamous carcinoma

Effect of Simultaneously Blocking VEGF,hTERT and Bcl-xl Expression on Laryngeal Squamous Carcinoma

The anticancer effect of EGFR-targeting artificial microRNA controlled by SLPI promoter in nasopharyngeal carcinoma

[Inhibitory Effect of P21waf1 on Squamous Cell Carcinoma of Larynx Mediated with EGF-R Targeting Polypeptide Gene Delivery System].